Traduction de «breast cancer with oral » (Français → Néerlandais) :

D’après D.M. Grabrick et al.: Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer.
Naar D.M. Grabrick et al.: Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer.

collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 without breast cancer from 54
individual data on 53 297 women with breast cancer and 100 239 without breast cancer from 54 epidemiological studies. Lancet

(Narod 2002) Narod SA, Dubé MP, Klijn J et al. Oral Contraceptives and the Risk of Breast Cancer in BRCA1 and BRCA2 Mutation
(Narod 2002) Narod SA, Dubé MP, Klijn J et al. Oral Contraceptives and the Risk of Breast Cancer in BRCA1 and BRCA2 Mutation Carriers. J Natl

Table 10: Evidence form HTA review : Breast cancer screening among women aged 40 – 49 Relative risks (intention to treat) with confidence reported for each study together with the results of a stepwise meta-analysis and cumulative CI Study ID Relative risk Confidence interval Cumulative RR Cumutlative CI UK Age Trial (UK) 0,83 (0,66-1,04) 0,83 (0,66-1,04) NBSS-1 (Canada) 0,97 (0,74-1,27) 0,89 (0,75-1,06) Malmö (Sweden) (0,58-1,77) 0,9 (0,76-1,06) Stockholm (Sweden) 1,08 (0,54-2,17) 0,91 (0,77-1,07) Göteborg (Sweden) 0,65 (0,40-1,05) 0,87 (0,75-1,02) HIP (USA) 0,75 (0,50-1,11) 0,86 (0,74-0,99) TCS (Sweden) 0,93 (0,63-1,36) 0,86 (0,75-0,99) Edinburgh (UK) 0,75 (0.48-1,18) 0,85 (0,75-0,97)
Table 8: Evidence form HTA review : Breast cancer screening among women aged 40 – 49 Relative risks (intention to treat) with confidence reported for each study together with the results of a stepwise meta-analysis and cumulative CI Study ID Relative risk Confidence interval Cumulative RR Cumutlative CI UK Age Trial (UK) 0,83 (0,66-1,04) 0,83 (0,66-1,04) NBSS-1 (Canada) 0,97 (0,74-1,27) 0,89 (0,75-1,06) Malmö (Sweden) (0,58-1,77) 0,9 (0,76-1,06) Stockholm (Sweden) 1,08 (0,54-2,17) 0,91 (0,77-1,07) Göteborg (Sweden) 0,65 (0,40-1,05) 0,87 (0,75-1,02) HIP (USA) 0,75 (0,50-1,11) 0,86 (0,74-0,99) TCS (Sweden) 0,93 (0,63-1,36) 0,86 (0,75-0,99) Edinburgh (UK) 0,75 (0.48-1,18) 0,85 (0,75-0,97)

in 2008, with large variations between types of cancer (in 2008: 84% of breast cancer patients, 74% lung cancer, 59% prostate cancer).
Overall, about 69% of cancer patients were discussed at the MOC – COM in 2008, with large variations between types of cancer (in 2008: 84% of breast cancer patients, 74% lung cancer, 59% prostate cancer).

69. Kolb T, Lichy J, Newhouse J. Occult cancer in women with dense breasts: detection with screening ultrasound-diagnostic yield and tumor characteristics.
70. Kolb T, Lichy J, Newhouse J. Occult cancer in women with dense breasts: detection with screening ultrasound-diagnostic yield and tumor characteristics.

18. Larsson LG, Andersson I, Bjurstam N, Fagerberg G, Frisell J, Tabar L, et al. Updated overview of the Swedish Randomized Trials on Breast Cancer Screening with Mammography: age group 40-49 at randomization.
18. Bjurstam N, Bjorneld L, Warwick J, Sala E, Duffy SW, Nystrom L, et al. The Gothenburg Breast Screening Trial.

11. Biesheuvel C, Barratt A, Howard K, Houssami N, Irwig L. Effects of study methods and biases on estimates of invasive breast cancer overdetection with mammography screening: a systematic review.
11. Jorgensen KJ, Gotzsche PC. Overdiagnosis in publicly organised mammography screening programmes: systematic review of incidence trends.

51. Nystrom L, Rutqvist LE, Wall S, Lindgren A, Lindqvist M, Ryden S, et al. Breast cancer screening with mammography: overview of Swedish randomised trials.
52. Nystrom L, Rutqvist LE, Wall S, Lindgren A, Lindqvist M, Ryden S, et al. Breast cancer screening with mammography: overview of Swedish randomised trials.

Lancet 360, 817-824 (2002) L.S. Kinsinger et R. Harris: Chemoprevention of breast cancer: a promising idea with an uncertain future.
Lancet 360, 817-824 (2002) L.S. Kinsinger en R. Harris: Chemoprevention of breast cancer: a promising idea with an uncertain future.